Taiko Pharmaceutical Co., Ltd. (JP:4574)
:4574
Top Page
Taiko Pharmaceutical Co., Ltd.
(4574)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥333.00
▲(9.18% Upside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by improving financial fundamentals (profitability and cash flow recovery with materially lower leverage), supported by positive technical momentum. Valuation is broadly reasonable but not especially compelling given the modest dividend yield, and the recent history of earnings/cash-flow volatility remains a key risk.
Positive Factors
Improved leverage
Material debt reduction to ~¥0.82B with sizable equity (~¥8.52B) meaningfully improves balance-sheet flexibility. This durable de-risking lowers refinancing and interest burden, increases capacity for R&D investment or partnerships, and strengthens resilience to sector shocks over the medium term.
Negative Factors
Earnings volatility
Multi-year swings—from strong profits in 2020 to heavy losses 2021–2023 and then recovery—highlight inconsistent earnings quality. This structural volatility complicates forecasting, budgeting and investment decisions, and raises execution risk for sustaining margins and cash conversion long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage
Material debt reduction to ~¥0.82B with sizable equity (~¥8.52B) meaningfully improves balance-sheet flexibility. This durable de-risking lowers refinancing and interest burden, increases capacity for R&D investment or partnerships, and strengthens resilience to sector shocks over the medium term.
Read all positive factors
Taiko Pharmaceutical Co., Ltd. (4574) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥14.87B
Dividend YieldN/A
Average Volume (3M)93.84K
Price to Earnings (P/E)16.2
Beta (1Y)0.75
Revenue Growth-5.41%
EPS GrowthN/A
CountryJP
Employees214
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.05
Shares Outstanding50,636,900
10 Day Avg. Volume93,940
30 Day Avg. Volume93,840
Financial Highlights & Ratios
PEG Ratio6.05
Price to Book (P/B)1.76
Price to Sales (P/S)2.34
P/FCF Ratio28.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.92
Revenue Forecast (FY)¥6.08B
Taiko Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, ...
How the Company Makes Money
Taiko Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which include both branded and generic medications. The company leverages its research and development capabilities to bring new drugs to market, oft...
Taiko Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
57
Neutral
Balance Sheet
72
Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.84B | 6.40B | 6.29B | 6.12B | 5.04B | 10.72B |
| Gross Profit | 3.31B | 3.48B | 3.67B | 2.58B | 1.08B | 2.75B |
| EBITDA | 893.00M | 724.00M | 882.00M | -2.85B | -3.75B | -5.57B |
| Net Income | 413.00M | 923.00M | 898.00M | -3.61B | -4.89B | -9.59B |
Balance Sheet | ||||||
| Total Assets | 11.68B | 12.27B | 12.91B | 13.22B | 15.05B | 22.54B |
| Cash, Cash Equivalents and Short-Term Investments | 4.14B | 4.26B | 4.53B | 5.48B | 3.50B | 6.10B |
| Total Debt | 1.32B | 816.00M | 2.03B | 3.25B | 3.81B | 4.77B |
| Total Liabilities | 3.73B | 3.75B | 4.95B | 6.48B | 7.00B | 9.72B |
| Stockholders Equity | 7.95B | 8.52B | 7.96B | 6.74B | 8.04B | 12.81B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 523.00M | 205.00M | -421.00M | -2.08B | -3.19B |
| Operating Cash Flow | 0.00 | 814.00M | 362.00M | -307.00M | -1.99B | -1.59B |
| Investing Cash Flow | 0.00 | 142.00M | -5.00M | 1.17B | 190.00M | -1.62B |
| Financing Cash Flow | 0.00 | -1.23B | -1.18B | 1.54B | -997.00M | 3.96B |
Taiko Pharmaceutical Co., Ltd. Technical Analysis
Positive
305.00
Price Trends
295.26
Positive
295.34
Positive
294.46
Positive
Market Momentum
0.03
Negative
50.66
Neutral
65.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4574, the sentiment is Positive. The current price of 305 is above the 20-day moving average (MA) of 295.15, above the 50-day MA of 295.26, and above the 200-day MA of 294.46, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 50.66 is Neutral, neither overbought nor oversold. The STOCH value of 65.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4574.
Taiko Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥14.87B | 16.22 | ― | ― | -5.41% | ― | |
64 Neutral | ¥6.20B | 11.64 | ― | 3.21% | 4.25% | ― | |
62 Neutral | ¥9.06B | 15.24 | ― | 2.55% | 3.23% | 42.87% | |
60 Neutral | ¥20.32B | 5.79 | ― | 3.71% | 7.50% | -281.41% | |
52 Neutral | ¥20.05B | 72.72 | ― | 3.65% | 9.53% | -155.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥11.70B | 7.11 | ― | 1.06% | 5.42% | -62.03% |
* Healthcare Sector Average
JP:4574
Taiko Pharmaceutical Co., Ltd.
297.00
33.00
12.50%
JP:2929
Pharma Foods International Co., Ltd.
692.00
-94.35
-12.00%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
337.00
18.68
5.87%
JP:4524
Morishita Jintan Co., Ltd.
2,220.00
218.42
10.91%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,296.00
183.09
8.67%
JP:4539
Nippon Chemiphar Co., Ltd.
1,718.00
280.87
19.54%
Taiko Pharmaceutical Co., Ltd. Corporate Events
Taiko Pharmaceutical Outlines FY2025 Results and FY2026 Outlook
Feb 17, 2026
Taiko Pharmaceutical Co., Ltd. released its consolidated financial results for the fiscal year ended December 31, 2025, outlining performance at the group level and by business segment. The disclosure also covers differences between prior full-yea...
Taiko Pharmaceutical Moves to Strengthen Board Oversight With Governance Rule Changes
Feb 13, 2026
Taiko Pharmaceutical plans to amend its Articles of Incorporation to strengthen governance by allowing the appointment of substitute directors who serve as Audit and Supervisory Committee Members if the number of sitting committee members falls be...
Taiko Pharmaceutical Beats FY2025 Forecasts, Resumes Dividend and Unlocks Reserves for Future Payouts
Feb 13, 2026
Taiko Pharmaceutical reported fiscal 2025 consolidated results modestly above its earlier net sales forecast and significantly ahead on profits, driven by stronger-than-expected performance in its Infection Control Business, favorable foreign exch...
Taiko Pharmaceutical Posts Higher FY2025 Profit, Plans Dividend Hike Despite Margin Pressure
Feb 13, 2026
Taiko Pharmaceutical reported consolidated net sales of ¥6.4 billion for the fiscal year ended December 31, 2025, a modest 1.7% increase year on year, while operating profit fell 27.1% to ¥459 million and ordinary profit dropped 29.8% to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.